In our study, the presence of a limited but representative fraction of cases with coexistence of somatic mutations in PIK3CA and BRAF or NRAS genes seems to somehow represent an indicator for including mutation analysis of PIK3CA into the initial (prior-to-therapy) strategies for molecular classification of melanoma patients. The gene discussed is BRAF; the disease is melanoma.